A study to evaluate the efficacy of 5 percent dextrose addition to lignocaine-dexamethasone injection in piriformis syndrome

INTERVENTION: Intervention1: USG guided greater trochanter injection: Group DL (Control): Ultrasound‐guided piriformis injection with 3 mL 0.5% lignocaine + dexamethasone 8 mg+ 5 mL sterile distilled water (total volume: 10 mL) Group DDL (Intervention): Ultrasound‐guided piriformis injection with 3 mL 0.5% lignocaine + 5 mL 5% dextrose + dexamethasone 8 mg (total volume: 10 mL) The total injectate volume will be standardized to 10 mL in both groups. Sterile distilled water (5 mL) will be added to the control group injectate to ensure identical volume and blinded appearance between the two preparations. Intervention2: USG guided piriformis injection: Ultrasound‐guided piriformis injection with 3 mL 0.5% lignocaine + 2 mL dexamethasone (8 mg) + 5mL 5% dextrose (total volume: 10 mL) Control Intervention1: USG guided piriformis injection: Ultrasound‐guided piriformis injection with 3 mL 0.5% lignocaine + 2 mL dexamethasone (8 mg)+ 5 mL sterile distilled water (total volume: 10 mL) CONDITION: Health Condition 1: M629‐ Disorder of muscle, unspecified PRIMARY OUTCOME: Number of patients having more than 50 percent reduction in NRS score in DL, lignocaine and dexamethasone and DDL, lignocaine, dexamethasone, 5 percent dextrose groupsTimepoint: 12 weeks SECONDARY OUTCOME: Incidence & nature of adverse effects in each group over the follow up period.Timepoint: Throughout follow up period NRS pain scores at every 2 weekly interval till 6 months post injection therapy.Timepoint: At 2 weekly interval till 6 months Number of patients having more than 50 percent reduction in NRS score in DL, lignocaine & dexamethasone, & DDL, lignocaine, dexamethasone, 5 percent dextrose groupsTimepoint: 24 weeks Oswestry Disability Inde Xscore at every monthly interval till 6 months post injection.Timepoint: At monthly interval till 6 months Total number of rescue analgesic i.e., tramadol & paracetamol doses consumed over the follow up period, compared between the DDL & DL groupsTimepoint: Throughout follow up period INCLUSION CRITERIA: Patients in the age group of 18 to 70 years with clinical diagnosis of piriformis syndrome, i.e., tenderness over piriformis with at least one positive provocative test.